On Monday, shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) marked $0.53 per share versus a previous $0.47 closing price. With having a 13.40% gain, an insight into the fundamental values of Neos Therapeutics, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. NEOS showed a fall of -65.03% within its YTD performance, with highs and lows between $0.45 – $1.98 during the period of 52 weeks, compared to the simple moving average of -42.41% in the period of the last 200 days.
RBC Capital Mkts equity researchers changed the status of Neos Therapeutics, Inc. (NASDAQ: NEOS) shares to a “Outperform” rating in the report published on August 9th, 2017. Other analysts, including Cantor Fitzgerald, also published their reports on NEOS shares. Cantor Fitzgerald repeated the rating from the previous report, marking NEOS under “Overweight” rating, in the report published on August 1st, 2017. Additionally, NEOS shares got another “Neutral” rating from UBS, setting a target price of $8 on the company’s shares, according to the report published in March 20th, 2017. On May 17th, 2016, RBC Capital Mkts Reiterated an Outperform rating and increased its price target from $33 to $29. On the other hand, Wells Fargo Initiated the “Outperform” rating for NEOS shares, as published in the report on February 19th, 2016. RBC Capital Mkts seems to be going bullish on the price of NEOS shares, based on the price prediction for NEOS, indicating that the shares will jump from $35 to $33, giving the shares “Outperform” rating based on their report from November 12th, 2015. Another “Outperform” rating came from RBC Capital Mkts, providing a prediction for $33 price target according to the report published in August 17th, 2015.
The present dividend yield for NEOS owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -16.00%, hinting the company’s progress in the upcoming progress.
In order to gain a clear insight on the performance of Neos Therapeutics, Inc. (NEOS) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of 197.30% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 0.50 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.
Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while NEOS is currently recording an average of 213.38K in volumes. The volatility of the stock on monthly basis is set at 9.97%, while the weekly volatility levels are marked at 10.15%with 3.02% of gain in the last seven days.
Neos Therapeutics, Inc. (NEOS) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare NEOS shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Neos Therapeutics, Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -0.38 is supported by the yearly EPS growth of 78.80%.
Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 1.30%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 36.10% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.Are Institutional Investors Increasing Stakes in NEOS Shares?
It appears that more than several institutional investors and hedge funds decided to increase stakes in NEOS in the recent period. That is how Nantahala Capital Management LLC now has an increase position in NEOS by 0.00% in the first quarter, owning 4.61 million shares of NEOS stocks, with the value of $2.44 million after the purchase of an additional 0 shares during the last quarter. In the meanwhile, Goldman Sachs & Co. LLC also increased their stake in NEOS shares changed 2.55% in the first quarter, which means that the company now owns 2.65 million shares of company, all valued at $1.4 million after the acquisition of additional 65,772 shares during the last quarter.
The Vanguard Group, Inc. acquired a new position in Neos Therapeutics, Inc. during the first quarter, with the value of $927109, and Renaissance Technologies LLC increased their stake in the company’s shares by 17.38% in the first quarter, now owning 121,900 shares valued at $436266 after the acquisition of the additional 823143 shares during the last quarter. In the end, Jacobs Levy Equity Management, In increased their position by 102.57% during the first quarter, now owning 391162 NEOS shares, now holding the value of $207316 in NEOS with the purchase of the additional 248,272 shares during the period of the last quarter. At the present, 36.10% of NEOS shares are in the ownership of institutional investors.